Finding – Page 5

Akeso, Summit’s PD-1/VEGF bispecific records another pivotal study win in NSCLC

3 months ago talkbio0Tagged Akeso, Combined, Ivonescimab, Keytruda, Non-Small Cell Lung Carcinoma, PD-1/VEGF, Pharmacotherapy, Safety, summit

Ivonescimab, Non-Small Cell Lung Carcinoma, Akeso, PD-1/VEGF, Keytruda, summit, Pharmacotherapy, Combined, Safety

Bristol Myers’ schizophrenia drug Cobenfy stumbles as adjunctive treatment, denting blockbuster plan

3 months ago talkbio0Tagged Adjunctive Orthodontic Procedure, Antipsychotic Agents, Cobenfy, Improvement, Myers, Schizophrenia, Single Agent Therapy, Statistical Significance

Cobenfy, Schizophrenia, Antipsychotic Agents, Adjunctive Orthodontic Procedure, Myers, Statistical Significance, Improvement, Single Agent Therapy

HR25: LifeSignals launches cardiac monitoring patch to compete with iRhythm, Philips

3 months ago talkbio0Tagged Heart, iRhythm, LifeSignals, Medical Devices, Philips, Plaque (lesion), Preventive monitoring

Preventive monitoring, Plaque (lesion), Philips, Heart, iRhythm, LifeSignals, Medical Devices

RFK Jr.’s FDA staff cuts claimed key user fee negotiators, threatening renewal talks with pharma: Reuters

3 months ago talkbio0Tagged Does speak, Drug Industry, Fees, HHS, Mediation, negotiators, Staff, United States Food and Drug Administration, user fee

United States Food and Drug Administration, Does speak, Staff, negotiators, HHS, Mediation, user fee, Fees, Drug Industry

UK approval brings GSK’s Blenrep back from the brink

3 months ago talkbio0Tagged Antibody-Drug Conjugates, Approved, Blenrep, Cessation of life, dexamethasone, DREAMM-8, Multiple Myeloma, Risk, UK

UK, Approved, Multiple Myeloma, DREAMM-8, dexamethasone, Blenrep, Antibody-Drug Conjugates, Risk, Cessation of life

Lilly’s oral GLP-1 succeeds in first Phase III test, delivering promising weight loss

3 months ago talkbio0Tagged Diabetes Mellitus, Non-Insulin-Dependent, Glucagon-Like Peptide 1, Hemoglobin A1c measurement, Injectables, Oral cavity, orforglipron, Phase 3 Clinical Trials, Safety, Weight Loss

orforglipron, Glucagon-Like Peptide 1, Weight Loss, Oral cavity, orforglipron, Phase 3 Clinical Trials, Diabetes Mellitus, Non-Insulin-Dependent, Hemoglobin A1c measurement, Safety, Injectables

Leaked HHS budget signals $40B in cuts, assumes ACA subsidies expire

3 months ago talkbio0Tagged Administration occupational activities, Agencies, assumes, Budgets, HHS, Leaked, Patient Protection and Affordable Care Act, Programs - Publication Format, proposal - intent, Subsidies

Budgets, HHS, Patient Protection and Affordable Care Act, Subsidies, Agencies, Leaked, Administration occupational activities, proposal – intent, assumes, Programs – Publication Format

FDA clears its first prescription migraine app, from Click Therapeutics

3 months ago talkbio0Tagged click, Click Therapeutics, CT-132, first, Migraine Disorders, United States Food and Drug Administration

United States Food and Drug Administration, CT-132, Migraine Disorders, Click Therapeutics, click, first

HHS Terminates Funding for GeoVax’s Next-Generation COVID-19 Vaccine: Impacts and Developments

3 months ago talkbio0Tagged BARDA, CHARGE Syndrome, Clinical Trials, COVID19 (disease), development aspects, GeoVax, Immunocompromised Host, pandemic preparedness, Project NextGen, Termination - Inactive Reason Code, Vaccines

GeoVax, HHS, BARDA, Project NextGen, COVID-19 vaccine, GEO-CM04S1, clinical trials, funding termination, immunocompromised, vaccine development, pandemic preparedness

Former FDA Officials Sound Alarm: Visible Changes May Be Tip of the Iceberg

3 months ago talkbio0Tagged Alarm device, Changing, Disease Outbreaks, drug safety, Icebergs, KAT5 wt Allele, Leadership, Policy, Previous, public health medicine (field), United States Food and Drug Administration, Vaccines, Visible

United States Food and Drug Administration, public health medicine (field), Changing, Vaccines, Leadership, Policy, drug safety, Previous, KAT5 wt Allele, Icebergs, Disease Outbreaks, Alarm device, Visible